Dr. Joan Mannick—mTOR's Role in Aging
Longevity by Design
00:00
Are You Taking Rapa Mysen in Off-Playbell?
I want to talk a bit about rapomizing or the autolog of that and the longevity. I do think it's important that even when the trials fail like an experiment in the lab, you learn a tremendous amount from that data set. We learned 65 to 74 is probably not the right age. It's two variable, 75 and above. And then you're asking about Rapa Mysen. We have no data yet on who, what, where, who should be taking Rapa Mysen. That all needs to be determined in clinical trials. Until that data is there, I think there is good data.
Transcript
Play full episode
